Patients with Hepatitis C on Direct-Acting Antiviral Agents' Response to the Elimination Program in Dammam City within 2018-2020

Manal S. Fawzy, Sana A. AlSadrah

International Journal of Biomedicine. 2022;12(3):396-400.
DOI: 10.21103/Article12(3)_OA8
Originally published September 5, 2022


Background: Hepatitis C virus (HCV) is a worldwide health challenge that imposes urgent interventions for prevention and control. We aimed to assess the response rate for the direct-acting antiviral agents (DAAs) regimen in HCV-infected patients attending the public health centers/hospitals in the Western region of Saudi Arabia.
Methods and Results: A retrospective study was followed, including data from the electronic medical records of HCV-infected adult patients in the period 2018-2020. Patients underwent HCV health education and treatment with DAAs according to the regional protocols. The type of treatment regimens provided to the included patients was recorded with the outcome (respondent vs. non-respondent) after 12 weeks post completion of treatment (SVR12) based on negative results (or less than the minimum detection levels using the specified assay) of HCV-RNA detected by polymerase chain reaction. The SVR12 was used for predicting SVR as it was reported to be applicable as SVR24. All cases with discontinuations, treatment modifications, and/or deaths were excluded. Included were a total of 505 adult patients recorded in 13 primary healthcare units and hepatitis treatment specialty clinics of hospitals in the Eastern region of Saudi Arabia during the specified period of the study. The patients were aged 30–73 years (mean age of 48.1±9.1 years), of which 229(45.3%) were females and 276(54.7%) males. Most patients received sofosbuvir/daclatasvir (86.1%), followed by glecaprevir/pibrentasvir (11.5%), and elbasvir/grazoprevir (2.4%). Overall, the SVR rate was 97.4% in the study population. Sofosbuvir/daclatasvir had an SVR12 of approximately 98.4%, while the rate of glecaprevir/pibrentasvir was 93.1%.
Conclusion: The present findings show an overall HCV cure rate of 97.4% of patients with HCV in response to the elimination program with DAAs in the Eastern region of Saudi Arabia, as indicated by high SVR12. This is an example of treating patients with HCV in a structured, supportive setting to help in the HCV elimination program.

hepatitis C virus • direct-acting antiviral agents • sustained virologic response
  1. Lingala S, Ghany MG. Natural History of Hepatitis C. Gastroenterol Clin North Am. 2015 Dec;44(4):717-34. doi: 10.1016/j.gtc.2015.07.003.
  2. Mahmud S, Chemaitelly HS, Kouyoumjian SP, Al Kanaani Z, Abu-Raddad LJ. Key associations for hepatitis C virus genotypes in the Middle East and North Africa. J Med Virol. 2020 Mar;92(3):386-393. doi: 10.1002/jmv.25614.
  3. Agnetti J, Desterke C, Gassama-Diagne A. Impact of HCV Infection on Hepatocyte Polarity and Plasticity. Pathogens. 2022 Mar 10;11(3):337. doi: 10.3390/pathogens11030337. 
  4. Abdel-Moneim AS, Bamaga MS, Shehab GM, Abu-Elsaad AA, Farahat FM. HCV infection among Saudi population: high prevalence of genotype 4 and increased viral clearance rate. PLoS One. 2012;7(1):e29781. doi: 10.1371/journal.pone.0029781. 
  5. Bawazir A, AlGusheri F, Jradi H, AlBalwi M, Abdel-Gader AG. Hepatitis C virus genotypes in Saudi Arabia: a future prediction and laboratory profile. Virol J. 2017 Nov 2;14(1):208. doi: 10.1186/s12985-017-0873-7.
  6. Mohamoud YA, Riome S, Abu-Raddad LJ. Epidemiology of hepatitis C virus in the Arabian Gulf countries: Systematic review and meta-analysis of prevalence. Int J Infect Dis. 2016 May;46:116-25. doi: 10.1016/j.ijid.2016.03.012.
  7. Mahmud S, Mumtaz GR, Chemaitelly H, Al Kanaani Z, Kouyoumjian SP, Hermez JG, Abu-Raddad LJ. The status of hepatitis C virus infection among people who inject drugs in the Middle East and North Africa. Addiction. 2020 Jul;115(7):1244-1262. doi: 10.1111/add.14944. 
  8. Alswaidi FM, O'Brien SJ. Is there a need to include HIV, HBV and HCV viruses in the Saudi premarital screening program on the basis of their prevalence and transmission risk factors? J Epidemiol Community Health. 2010 Nov;64(11):989-97. doi: 10.1136/jech.2009.093302. 
  9. El-Hazmi MM. Prevalence of HBV, HCV, HIV-1, 2 and HTLV-I/II infections among blood donors in a teaching hospital in the Central region of Saudi Arabia. Saudi Med J. 2004 Jan;25(1):26-33.
  10. Bashawri LA, Fawaz NA, Ahmad MS, Qadi AA, Almawi WY. Prevalence of seromarkers of HBV and HCV among blood donors in eastern Saudi Arabia, 1998-2001. Clin Lab Haematol. 2004 Jun;26(3):225-8. doi: 10.1111/j.1365-2257.2004.00601.x. 
  11. Madani TA. Hepatitis C virus infections reported in Saudi Arabia over 11 years of surveillance. Ann Saudi Med. 2007 May-Jun;27(3):191-4. doi: 10.5144/0256-4947.2007.191. 
  12. Abdo AA, Sanai FM. Viral hepatitis in Saudi Arabia. An unfinished story. Saudi Med J. 2015 Jul;36(7):785-6. doi: 10.15537/smj.2015.7.12457.
  13. Popping S, Bade D, Boucher C, van der Valk M, El-Sayed M, Sigurour O, Sypsa V, Morgan T, Gamkrelidze A, Mukabatsinda C, Deuffic-Burban S, Ninburg M, Feld J, Hellard M, Ward J. The global campaign to eliminate HBV and HCV infection: International Viral Hepatitis Elimination Meeting and core indicators for development towards the 2030 elimination goals. J Virus Erad. 2019 Jan 1;5(1):60-66.
  14. Tsubota A, Fujise K, Namiki Y, Tada N. Peginterferon and ribavirin treatment for hepatitis C virus infection. World J Gastroenterol. 2011 Jan 28;17(4):419-32. doi: 10.3748/wjg.v17.i4.419.
  15. Mathur P, Kottilil S, Wilson E. Use of Ribavirin for Hepatitis C Treatment in the Modern Direct-acting Antiviral Era. J Clin Transl Hepatol. 2018 Dec 28;6(4):431-437. doi: 10.14218/JCTH.2018.00007. 
  16. Alghamdi AS, Sanai FM, Ismail M, Alghamdi H, Alswat K, Alqutub A, Altraif I, Shah H, Alfaleh FZ; Saudi Association for the Study of Liver Diseases and Transplantation. SASLT practice guidelines: management of hepatitis C virus infection. Saudi J Gastroenterol. 2012 Sep;18 Suppl(Suppl 1):S1-32. doi: 10.4103/1319-3767.101155. 
  17. Altraif I. Can hepatitis C virus be eliminated by 2030? Saudi Arabia as an example. Saudi Med J. 2018 Aug;39(8):842-845. doi: 10.15537/smj.2018.8.22467. 
  18. Babatin MA, AlGhamdi AS, Assiri AM, AlBiladi H, AlOthmani HS, Mogharbel MH, Mahallawi W, Asselah T, Sanai FM. Treatment efficacy of ledipasvir/sofosbuvir for 8 weeks in non-cirrhotic chronic hepatitis C genotype 4 patients. Saudi J Gastroenterol. 2019 Jan-Feb;25(1):55-60. doi: 10.4103/sjg.SJG_189_18.
  19. Alotaibi AS, Shamas N, Ansari UU, Sanai FM, Alshahrani A, Fathelrahman AI, Aseeri MA. Impact of Drug Use Policy on the Appropriate Use of Direct Acting Antiviral Agents for Hepatitis C in Saudi Arabia. J Pharm Bioallied Sci. 2021 Jul-Sep;13(3):317-324. doi: 10.4103/jpbs.jpbs_166_21. 
  20. Mennini FS, Marcellusi A, Andreoni M, Gasbarrini A, Salomone S, Craxì A. Health policy model: long-term predictive results associated with the management of hepatitis C virus-induced diseases in Italy. Clinicoecon Outcomes Res. 2014 Jun 19;6:303-10. doi: 10.2147/CEOR.S62092. 
  21. Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, Schultz M, Davis MN, Kayali Z, Reddy KR, Jacobson IM, Kowdley KV, Nyberg L, Subramanian GM, Hyland RH, Arterburn S, Jiang D, McNally J, Brainard D, Symonds WT, McHutchison JG, Sheikh AM, Younossi Z, Gane EJ. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013 May 16;368(20):1878-87. doi: 10.1056/NEJMoa1214853.
  22. Poordad F, Lawitz E, Kowdley KV, Cohen DE, Podsadecki T, Siggelkow S, Heckaman M, Larsen L, Menon R, Koev G, Tripathi R, Pilot-Matias T, Bernstein B. Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med. 2013 Jan 3;368(1):45-53. doi: 10.1056/NEJMoa1208809. 
  23. Meyer JP, Moghimi Y, Marcus R, Lim JK, Litwin AH, Altice FL. Evidence-based interventions to enhance assessment, treatment, and adherence in the chronic Hepatitis C care continuum. Int J Drug Policy. 2015 Oct;26(10):922-35. doi: 10.1016/j.drugpo.2015.05.002. 
  24. Boland GM, Chang GJ, Haynes AB, Chiang YJ, Chagpar R, Xing Y, Hu CY, Feig BW, You YN, Cormier JN. Association between adherence to National Comprehensive Cancer Network treatment guidelines and improved survival in patients with colon cancer. Cancer. 2013 Apr 15;119(8):1593-601. doi: 10.1002/cncr.27935.
  25. Morillo Verdugo R, Ramírez Herráiz E, Fernández-Del Olmo R, Roig Bonet M, Valdivia García M. Adherence to disease-modifying treatments in patients with multiple sclerosis in Spain. Patient Prefer Adherence. 2019 Feb 13;13:261-272. doi: 10.2147/PPA.S187983. 
  26. Altice F, Evuarherhe O, Shina S, Carter G, Beaubrun AC. Adherence to HIV treatment regimens: systematic literature review and meta-analysis. Patient Prefer Adherence. 2019 Apr 3;13:475-490. doi: 10.2147/PPA.S192735. 
  27. Balkhy HH, El-Saed A, Sanai FM, Alqahtani M, Alonaizi M, Niazy N, Aljumah A. Magnitude and causes of loss to follow-up among patients with viral hepatitis at a tertiary care hospital in Saudi Arabia. J Infect Public Health. 2017 Jul-Aug;10(4):379-387. doi: 10.1016/j.jiph.2016.06.012. 
  28. Younossi ZM, Stepanova M, Henry L, Nader F, Younossi Y, Hunt S. Adherence to treatment of chronic hepatitis C: from interferon containing regimens to interferon and ribavirin free regimens. Medicine (Baltimore). 2016 Jul;95(28):e4151. doi: 10.1097/MD.0000000000004151. 
  29. Martinot-Peignoux M, Stern C, Maylin S, Ripault MP, Boyer N, Leclere L, Castelnau C, Giuily N, El Ray A, Cardoso AC, Moucari R, Asselah T, Marcellin P. Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin. Hepatology. 2010 Apr;51(4):1122-6. doi: 10.1002/hep.23444. 
  30. Kemp W, Roberts S. Pegylated interferon and ribavirin for the treatment of chronic hepatitis C. Clinical Medicine Insights: Therapeutics. 2011;3:CMT-S4015.
  31. Afdhal NH. Hepatitis C viral infection in difficult-to-treat populations: An overview. Clin Liver Dis (Hoboken). 2012 Jul 23;1(3):63-64. doi: 10.1002/cld.57. 
  32. Asselah T, Marcellin P. Interferon free therapy with direct acting antivirals for HCV. Liver Int. 2013 Feb;33 Suppl 1:93-104. doi: 10.1111/liv.12076. 
  33. Al Traif I, Al Balwi MA, Abdulkarim I, Handoo FA, Alqhamdi HS, Alotaibi M, Aljumah A, Al Ashqar HI, Bzeizi K, Al Quaiz M, Alalwan A, Al Hamoudi W, Sanai F, Abdo A. HCV genotypes among 1013 Saudi nationals: a multicenter study. Ann Saudi Med. 2013 Jan-Feb;33(1):10-2. doi: 10.5144/0256-4947.2013.10. 
  34. Sanai FM, Altraif IH, Alswat K, AlZanbagi A, Babatin MA, AlMousa A, Almutairi NH, Aljawad MS, Alghamdi AS, Aljumah AA, Alalwan AM, Al-Hamoudi WK, Assiri AM, Dahlan Y, Alsahafi A, Alothmani HS, AlSaleemi MS, Mousa WA, Albenmousa A, Awny A, Albiladi H, Abdo AA, AlGhamdi H. Real life efficacy of ledipasvir/sofosbuvir in hepatitis C genotype 4-infected patients with advanced liver fibrosis and decompensated cirrhosis. J Infect. 2018 Jun;76(6):536-542. doi: 10.1016/j.jinf.2018.04.001. 
  35. Hashim A, Almahdi F, Albaba EA, Barkia O, Alkasam R, Almahmoud A, Nabil A, Alsulaimani A, Mosli M. Efficacy of DAAs in the Treatment of Chronic HCV: Real-World Data from the Private Health-Care Sector of the Kingdom of Saudi Arabia. J Epidemiol Glob Health. 2020 Jun;10(2):178-183. doi: 10.2991/jegh.k.200117.002. 
  36. Yen HH, Su PY, Liu IL, Zeng YY, Huang SP, Hsu YC, Yang CW, Chen YY. Direct-acting antiviral treatment for Hepatitis C Virus in geriatric patients: a real-world retrospective comparison between early and late elderly patients. PeerJ. 2021 Mar 16;9:e10944. doi: 10.7717/peerj.10944. 
  37. Yen HH, Chen YY, Lai JH, Chen HM, Yao CT, Huang SP, Liu IL, Zeng YH, Yang FC, Siao FY, Chen MW, Su PY. Pan-Genotypic Direct-Acting Antiviral Agents for Undetermined or Mixed-Genotype Hepatitis C Infection: A Real-World Multi-Center Effectiveness Analysis. J Clin Med. 2022 Mar 27;11(7):1853. doi: 10.3390/jcm11071853. 
  38. Poordad F, Dieterich D. Treating hepatitis C: current standard of care and emerging direct-acting antiviral agents. J Viral Hepat. 2012 Jul;19(7):449-64. doi: 10.1111/j.1365-2893.2012.01617.x.
  39. Jiménez-Pérez M, González-Grande R, España Contreras P, Pinazo Martínez I, de la Cruz Lombardo J, Olmedo Martín R. Treatment of chronic hepatitis C with direct-acting antivirals: The role of resistance. World J Gastroenterol. 2016 Aug 7;22(29):6573-81. doi: 10.3748/wjg.v22.i29.6573. 
  40. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, Jacobson I, Lawitz E, Lok AS, Hinestrosa F, Thuluvath PJ, Schwartz H, Nelson DR, Everson GT, Eley T, Wind-Rotolo M, Huang SP, Gao M, Hernandez D, McPhee F, Sherman D, Hindes R, Symonds W, Pasquinelli C, Grasela DM; AI444040 Study Group. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014 Jan 16;370(3):211-21. doi: 10.1056/NEJMoa1306218. Erratum in: N Engl J Med. 2014 Apr 10;370(15):1469. P
  41. Nelson DR, Cooper JN, Lalezari JP, Lawitz E, Pockros PJ, Gitlin N, Freilich BF, Younes ZH, Harlan W, Ghalib R, Oguchi G, Thuluvath PJ, Ortiz-Lasanta G, Rabinovitz M, Bernstein D, Bennett M, Hawkins T, Ravendhran N, Sheikh AM, Varunok P, Kowdley KV, Hennicken D, McPhee F, Rana K, Hughes EA; ALLY-3 Study Team. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology. 2015 Apr;61(4):1127-35. doi: 10.1002/hep.27726.
  42. Merat S; SD1000 Research Team. SD1000: High Sustained Viral Response Rate in 1361 Patients With Hepatitis C Genotypes 1, 2, 3, and 4 Using a Low-cost, Fixed-dose Combination Tablet of Generic Sofosbuvir and Daclatasvir: A Multicenter, Phase III Clinical Trial. Clin Infect Dis. 2020 May 6;70(10):2206-2212. doi: 10.1093/cid/ciz628. Erratum in: Clin Infect Dis. 2020 May 23;70(11):2459. Erratum in: Clin Infect Dis. 2021 Jul 1;73(1):172. 
  43. Summa V, Ludmerer SW, McCauley JA, Fandozzi C, Burlein C, Claudio G, Coleman PJ, Dimuzio JM, Ferrara M, Di Filippo M, Gates AT, Graham DJ, Harper S, Hazuda DJ, Huang Q, McHale C, Monteagudo E, Pucci V, Rowley M, Rudd MT, Soriano A, Stahlhut MW, Vacca JP, Olsen DB, Liverton NJ, Carroll SS. MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants. Antimicrob Agents Chemother. 2012 Aug;56(8):4161-7. doi: 10.1128/AAC.00324-12. Epub 2012 May 21. Erratum in: Antimicrob Agents Chemother. 2014 Aug;58(8):4995. Huang, Qian [added].
  44. Forns X, Lee SS, Valdes J, Lens S, Ghalib R, Aguilar H, Felizarta F, Hassanein T, Hinrichsen H, Rincon D, Morillas R, Zeuzem S, Horsmans Y, Nelson DR, Yu Y, Krishnan P, Lin CW, Kort JJ, Mensa FJ. Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial. Lancet Infect Dis. 2017 Oct;17(10):1062-1068. doi: 10.1016/S1473-3099(17)30496-6. 
  45. Asselah T, Kowdley KV, Zadeikis N, Wang S, Hassanein T, Horsmans Y, Colombo M, Calinas F, Aguilar H, de Ledinghen V, Mantry PS, Hezode C, Marinho RT, Agarwal K, Nevens F, Elkhashab M, Kort J, Liu R, Ng TI, Krishnan P, Lin CW, Mensa FJ. Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis. Clin Gastroenterol Hepatol. 2018 Mar;16(3):417-426. doi: 10.1016/j.cgh.2017.09.027. 
  46. Asselah T, Lee SS, Yao BB, Nguyen T, Wong F, Mahomed A, Lim SG, Abergel A, Sasadeusz J, Gane E, Zadeikis N, Schnell G, Zhang Z, Porcalla A, Mensa FJ, Nguyen K. Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus genotype 5 or 6 infection (ENDURANCE-5,6): an open-label, multicentre, phase 3b trial. Lancet Gastroenterol Hepatol. 2019 Jan;4(1):45-51. doi: 10.1016/S2468-1253(18)30341-8. 
  47. Brown RS Jr, Buti M, Rodrigues L, Chulanov V, Chuang WL, Aguilar H, Horváth G, Zuckerman E, Carrion BR, Rodriguez-Perez F, Urbánek P, Abergel A, Cohen E, Lovell SS, Schnell G, Lin CW, Zha J, Wang S, Trinh R, Mensa FJ, Burroughs M, Felizarta F. Glecaprevir/pibrentasvir for 8 weeks in treatment-naïve patients with chronic HCV genotypes 1-6 and compensated cirrhosis: The EXPEDITION-8 trial. J Hepatol. 2020 Mar;72(3):441-449. doi: 10.1016/j.jhep.2019.10.020. 
  48. Jacobson IM, Lawitz E, Kwo PY, Hézode C, Peng CY, Howe AYM, Hwang P, Wahl J, Robertson M, Barr E, Haber BA. Safety and Efficacy of Elbasvir/Grazoprevir in Patients With Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis. Gastroenterology. 2017 May;152(6):1372-1382.e2. doi: 10.1053/j.gastro.2017.01.050.
  49. Burstow NJ, Mohamed Z, Gomaa AI, Sonderup MW, Cook NA, Waked I, Spearman CW, Taylor-Robinson SD. Hepatitis C treatment: where are we now? Int J Gen Med. 2017 Feb 17;10:39-52. doi: 10.2147/IJGM.S127689. 

Download Article
Received May 24, 2022.
Accepted July 1, 2022.
©2022 International Medical Research and Development Corporation.